Effectiveness of the available COVID-19 primary and booster vaccination schemes against laboratory-confirmed infections during the different waves. by Rima Moghnieh (679199)

Subjects:

Diagrammatic illustration showing the time-course of the experimental set-up as well as the experimental endpoints. by Bryan S. Margulies (21492667)

Subjects:

Mice in the NTC and MBC-005 treatment groups were evaluated for bioluminescent signaling at 6-, 13-, and 21-days after tumor inoculation. by Bryan S. Margulies (21492667)

Subjects:

Echogenic properties were assessed using a portable ultrasound, similar to the devices that are used clinically. by Bryan S. Margulies (21492667)

Subjects:

MCF7 cultures were treated with either MBC-005 or doxorubicin. by Bryan S. Margulies (21492667)

Subjects:

Cox proportional hazard ratios. by Bryan S. Margulies (21492667)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against acute-care hospitalization attributed to laboratory-confirmed infections during the differen... by Rima Moghnieh (679199)

Subjects:

Liver samples were stained with hematoxylin and eosin and imaged at 4x. by Bryan S. Margulies (21492667)

Subjects:

Bioluminescent Doubling Time. by Bryan S. Margulies (21492667)

Subjects:

Study Design. by Bryan S. Margulies (21492667)

Subjects:

Liver weights were normalized by the mouse body weight to derive the %liver weight. by Bryan S. Margulies (21492667)

Subjects:

Immunogenicity assessment groups based on the primary and booster vaccination schemes and timeframe from the second or booster dose. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.4/BA.5 variant wave. by Rima Moghnieh (679199)

Subjects:

Histomorphometric analysis of the tumor volume fraction (V_f) in the liver and necrosis volume fraction. by Bryan S. Margulies (21492667)

Subjects:

(A) Release rate (i.e., elution) of N-allyl noroxymorphone hydrochloride evaluated using UPLC from two samples of MBC-005. The equations predict that at 24-hours there will be betw... by Bryan S. Margulies (21492667)

Subjects:

The MTT assay and the LDH assay were used to assess the effects of the hydrogel component of MBC-005 on tumor cell number and cell death. by Bryan S. Margulies (21492667)

Subjects:

The spheroid assay is used to assess long-term effects of therapy on tumor cell by culturing the tumor cells in a micro-mass, which is a 3D tumor mass used as a surrogate for in vi... by Bryan S. Margulies (21492667)

Subjects:

Survival in mice with liver metastases after MBC-005 TREATMENT. by Bryan S. Margulies (21492667)

Subjects:

Humoral immune responses to SARS-CoV-2 spike protein following various primary vaccination schemes and booster doses with Sinopharm or Pfizer vaccines among COVID-19-naïve particip... by Rima Moghnieh (679199)

Subjects:

Inhibitor versus the normalized dose response curves. by Bryan S. Margulies (21492667)

Subjects: